Background: Symptoms and signs of thyrotoxicosis are nonspecific and assessing its clinical status is difficult with conventional physical examinations and history taking. Increased heart rate (HR) is one of the easiest signs to quantify this, and current wearable devices can monitor HR.
Objective: We assessed the association between thyroid function and resting HR measured by a wearable activity tracker (WD-rHR) and evaluated the clinical feasibility of using this method in patients with thyrotoxicosis.
Methods: Thirty patients with thyrotoxicosis and 10 controls were included in the study. Participants were instructed to use the wearable activity tracker during the study period so that activity and HR data could be collected. The primary study outcomes were verification of changes in WD-rHR during thyrotoxicosis treatment and associations between WD-rHR and thyroid function. Linear and logistic model generalized estimating equation analyses were performed and the results were compared to conventionally obtained resting HR during clinic visits (on-site resting HR) and the Hyperthyroidism Symptom Scale.
Results: WD-rHR was higher in thyrotoxic patients than in the control groups and decreased in association with improvement of thyrotoxicosis. A one standard deviation–increase of WD-rHR of about 11 beats per minute (bpm) was associated with the increase of serum free T4 levels (beta=.492, 95% CI 0.367-0.616, P<.001) and thyrotoxicosis risk (odds ratio [OR] 3.840, 95% CI 2.113-6.978, P<.001). Although the Hyperthyroidism Symptom Scale showed similar results with WD-rHR, a 1 SD-increase of on-site rHR (about 16 beats per minute) showed a relatively lower beta and OR (beta=.396, 95% CI 0.204-0.588, P<.001; OR 2.114, 95% CI 1.365-3.273, P<.001) compared with WD-rHR.
Conclusions: Heart rate data measured by a wearable device showed reasonable predictability of thyroid function. This simple, easy-to-measure parameter is clinically feasible and has the potential to manage thyroid dysfunction.
Trial Registration: ClinicalTrials.gov NCT03009357; https://clinicaltrials.gov/ct2/show/NCT03009357 (Archived by WebCite at http://www.webcitation.org/70h55Llyg)
Thyrotoxicosis is a clinical syndrome resulting from the high concentration of free thyroxine (T4) and free triiodothyronine (T3). The prevalence of thyrotoxicosis is approximately 2%, and its most common cause (ie, 60%-90%) is Graves’ disease (GD) which is an autoimmune disease that stimulates the thyroid gland to produce and release thyroid hormone [- ]. Thyrotoxicosis results in various symptoms and signs, including fatigue, anxiety, palpitations, sweating, heat intolerance, disturbed sleep, and weight loss because the thyroid hormone affects many different organs [ ]. These clinical manifestations are relatively nonspecific and vary depending on factors such as patient age and sex, disease duration, and etiology [ , ]. Although palpitation and increased heart rate (HR) are among the most frequent symptoms and signs [ ], and the easiest to quantify, HR can easily be affected by other factors such as the patient’s emotional state, body position, and physical activities. Therefore, it is difficult to assess disease status based solely on patient HR that is either self-reported or obtained conventionally in the clinic during a specific moment. Although researchers have developed assessment tools that use parameters associated with symptoms and signs of thyrotoxicosis, most are questionnaire-based scoring systems that require time and educated scorers [ , ]. Thyrotoxicosis is diagnosed when a thyroid function test (TFT) shows increased serum thyroid hormone levels. This test is often delayed because patients tend to visit the clinic in severe status due to the nonspecific symptoms of thyrotoxicosis. Therefore, a simple, easy-to-measure parameter to predict thyroid status would be useful for thyrotoxicosis management.
The popularity of wearable activity trackers has grown considerably in recent years. The American College of Sports Medicine survey of fitness trends reported that wearable technology was the top-rated trend in 2016 . Forecasts indicate that wearable activity tracker sales will exceed 82 million by the end of 2019, 2.5 times the expected sales volume in 2016 [ ]. These devices are typically worn on the wrist or hip and provide the user with information about their physical activity, such as steps taken, vertical and horizontal moving distance, and sleep patterns. Recently developed devices can measure HR using photoplethysmography, which measures a differential reflection of light from the skin, based on the pulsatility of superficial blood vessels [ ]. Many studies on the accuracy of these wrist-worn HR monitors have been published, showing relatively accurate HR during the resting state [ , ]. It is easy to collect detailed longitudinal HR data and physical activity with these wearable devices, and these data can provide more information than intermittently measured HR. This makes it now possible to collect and analyze more detailed and precise HR data, which is a crucial parameter changed in thyrotoxicosis. However, few trials have evaluated wearable devices for use in assessing thyroid dysfunction.
Therefore, the objectives of the present study were to investigate whether and how well HR data collected by commercially available activity trackers reflect thyroid function across the clinical course of thyrotoxicosis. Using this approach, the clinical feasibility of wearable devices for the management of thyroid dysfunction was evaluated.
Study Design and Participants
This was a single-center prospective observational study. Subjects were recruited from the outpatient clinic of the endocrinology department at Seoul National University Bundang Hospital (SNUBH).
For the thyrotoxicosis group, patients 15-60 years of age who had been diagnosed with newly developed or recurrent thyrotoxicosis were eligible to participate. Participants needed to own a mobile phone and to be able to use a wearable device and its mobile application. Among those for whom the etiology of thyrotoxicosis was GD, only patients who had planned treatment with antithyroid drugs (ATD) were included so that their clinical course could be followed during medical treatment. We prescribed methimazole as the first choice ATD unless the subjects were contraindicated. No subject had a contraindication for methimazole or adverse events during the administration of methimazole. Inclusion and exclusion criteria are listed in. Prescribing beta blockers is a standard treatment for relief of thyrotoxicosis symptoms; we prescribed short-acting beta blocker propranolol to symptomatic patients to minimize its impact on the study. A total of 37 patients were screened for participation. A total of 30 patients were finally enrolled, and 2 withdrew during the study. One participant withdrew because of a skin reaction to the device (ie, Fitbit Charge HR) on their wrist; the investigators withdrew the second because of poor adherence to using the device. There were 25 and 3 patients diagnosed with GD and thyroiditis for the etiology of thyrotoxicosis, respectively, who completed the study.
Healthy adults without a history of thyroid disease were included in the control group. Consistent with the thyrotoxicosis group, participants needed to be able to use a wearable device and the mobile application. These participants were screened to ensure they were not taking medications affecting HR, including beta blockers. There were 13 potential participants screened, and 10 were enrolled in the control group. All participants were informed about the study and provided written informed consent. This study was approved by the SNUBH Institutional Review Board (IRB #B-1609-363-004) and registered on ClinicalTrials.gov (trial registration #NCT03009357).
The study design is shown in. On the first visit, potential candidates were provided with a device and brief on-site instructions for its use. They were instructed to wear the device as much as possible throughout the day and during sleep. We also explained that if they did not wear the device or synchronize it with the application for more than five consecutive days, they could be withdrawn from the study due to poor adherence.
After a one- to two-week screening period, patients visited the clinic to confirm the results of the TFT and other tests to determine the etiology (eg, autoantibodies, thyroid scan) and to start appropriate treatment. At this visit, those who met the inclusion criteria were enrolled. Patients with GD were prescribed a specific ATD dose, as determined by the endocrinologist. Patients with thyrotoxicosis caused by thyroiditis were reassured that their symptoms and signs were benign and self-limited. Patients taking propranolol were instructed to take the medication when their symptoms were severe and to inform the investigator of their dosing times, which were recorded in the case report form (CRF). Regardless of the etiology of thyrotoxicosis, all patients had monthly follow-ups, during which time they underwent blood tests, including TFT. Their ATD dose was adjusted as necessary. The study ended after each patient’s third visit; however, the study duration could be extended at the discretion of the investigator with the patient’s consent if their TFT was not fully restored. At each visit, anthropometric data were collected, and vital signs were measured.
Healthy adults were recruited into the control group through an official SNUBH announcement. Control participants visited the hospital on the same schedule as the thyrotoxic patients. They were given the same instruction about using the device and mobile application, and they were also instructed to wear the device all day and to inform to the investigator of any medication changes, which were recorded in the CRF. Control participants’ visit schedules and blood tests were consistent with those of thyrotoxic patients, but the duration of their study participation was not extended.
Wearable Devices and Applications
We used the Fitbit Charge HR or Fitbit Charge 2 (Fitbit, San Francisco, CA) and the Fitbit application for iOS (Apple, Cupertino, CA) or Android (Google, Mountain View, CA). The firmware versions of these devices were 18.128 for Fitbit Charge HR and 22.53.4 for Fitbit Charge 2 at the end of the study, and the latest version was maintained continuously over the study period. Although we started the study with Fitbit Charge HR, when Fitbit released Fitbit Charge 2, they discontinued production of the former device. Therefore, we used Fitbit Charge 2 with study participants enrolled after March 2017 (n=7 in the control group). However, these 2 models share a common sensor and data processing algorithm for both activity tracking and HR measurement. Activity and HR data are collected by the 3-axis accelerometer and plethysmography sensor, respectively. These sensors are equipped with the device. During the study period, each participant’s Fitbit account information, including identification and password, were shared with researchers, allowing us to access their online Fitbit account  to monitor their synchronization status between the Fitbit data server and tracking device. After the end of their participation, we separated the account from the device, and each participant retained their account.
Hyperthyroidism Symptom Scale
To assess their hyperthyroidism clinical status at each clinic visit, the endocrinologist overseeing this study evaluated the patients using the Hyperthyroidism Symptom Scale (HSS) [, ]. The HSS consists of 10 items, including 1 psychometric item (ie, nervousness) and 9 items about physical response in the thyrotoxic state. A total of 8 items were evaluated through history taking: nervousness, sweating, heat intolerance, hyperactivity, weakness, diarrhea, appetite, and assessment of daily function. Physical examination evaluated the remaining 2 items: tremor and hyperdynamic precordium. Item scores were totaled to obtain an overall HSS score, which could range from 0-40 points.
Definition of Resting Heart Rate
Anthropometric and Biochemical Measurements
We measured the subjects’ height and weight while wearing light clothing and without shoes to the nearest 0.1 cm and 0.1 kg, respectively. Body mass index was calculated by determining the ratio between weight and the square of the height and expressed in kilograms per square meter. Right arm blood pressure was measured with the subject in a seated position after at least 10 minutes of resting. Biochemical measurements including TFT are listed in the. The free T4 assay had an analytic sensitivity of 0.05 nanograms per deciliter (ng/dL), and TSH had an analytical sensitivity of 0.04 milli-international units per liter (mIU/L) and functional sensitivity of 0.07 mIU/L. The reference ranges for free T4 and TSH were 0.89-1.79 ng/dl and 0.3-4.0 mIU/L, respectively. Thyrotoxicosis was defined based on the results of the TFT (ie, overt thyrotoxicosis was defined as higher free T4 and lower TSH levels than respective reference ranges; subclinical thyrotoxicosis was defined as normal free T4 and lower TSH levels). All subjects were examined for the presence of anti-TSH receptor antibody by radioimmunoassay (Cis Bio International), and the cutoff for positivity was greater than 1.0 units per milliliter (U/mL).
Data were expressed as the mean (SD) or median (interquartile range). To compare variables between the patient and control groups, we used Student t test or the Mann Whitney U test for continuous variables and the chi-square test or Fisher exact probability test for categorical variables. Repeated measures analysis of variance (ANOVA) or Friedman test were used to analyze changes in thyroid hormone levels and associated parameters (HSS, on-site rHR, and WD-rHR) during the study period. The relationship between thyroid hormone levels and each associated parameter was determined by linear model generalized estimating equation (GEE) analyses. The relationship between thyrotoxicosis, defined as 1.8 ng/dL or more of free T4, and each associated parameter was assessed using binary logistic model GEE analyses. Odds ratios (OR) and 95% CI were computed per one standard deviation increase in these variables to the risk of thyrotoxicosis. A two-tailed P<.05 was considered statistically significant. All statistical analyses and data preparation were performed using IBM SPSS Statistics (version 20.0; IBM Corp, Armonk, NY, USA) and R (version 3.3.3; The R Foundation for Statistical Computing, Vienna, Austria).
Participant Baseline Characteristics
Participant baseline characteristics are summarized in. There were no differences in age, sex ratio, or body mass index between the 28 patients with thyrotoxicosis (ie, 25 diagnosed with GD, 3 with thyroiditis) and the 10 controls. As expected, on-site rHR in the thyrotoxicosis group was significantly higher than that in the control group. Blood pressure did not differ between the groups. There was a significantly higher HSS score and free T4, and lower TSH, in the thyrotoxic patients compared with the controls. Also, there were significant differences between the 2 groups on several parameters known to be related to thyrotoxicosis, including total cholesterol, serum creatinine, platelets, and liver enzymes. The mean duration of observation was 3.27 (SD 1.21) months for all subjects, which was longer in thyrotoxic patients than in controls.
Changes in Thyroid Function and Associated Parameters
In thyrotoxic patients, thyrotoxicosis improved with treatment, as shown by decreased serum free T4 levels through the third visit. Serum TSH levels remained unchanged during the observation period (). Thyroid function was not fully restored in all patients by the end of the study, at which time 6 patients improved to a euthyroid state, 17 remained sub-clinically thyrotoxic, and 5 were still overtly thyrotoxic (data not shown). HSS, on-site rHR, and WD-rHRs also decreased with treatment in the thyrotoxicosis group through the third visit ( and ). This study was scheduled to terminate after the third visit but was extended, with patient consent, in those whose thyroid function was not restored. Thus, increased free T4, HSS, and WD-rHRs were apparent after the fourth visit because only patients whose thyroid function had not yet recovered were retained in the study through a fifth visit. The control group completed the study at the third visit, and none of their thyroid hormone levels or associated parameters differed between visits.
|Characteristics||Thyrotoxicosis (n=28)||Control (n=10)||P value|
|Age (years), mean (SD)||34.9 (10.9)||34.1 (5.9)||.78a|
|Gender, n (%)|
|Male||10 (36)||3 (30)||.53b|
|Female||18 (64)||7 (70)|
|Body mass index (kg/m2), mean (SD)||20.6 (4.7)||20.7 (1.6)||.93a|
|Blood pressure (mmHg), mean (SD)|
|Systolic blood pressure||130.2 (14.3)||124.6 (11.4)||.27a|
|Diastolic blood pressure||78.1 (10.6)||70.6 (9.6)||.06a|
|On-site resting heart rate (bpmc), mean (SD)||101.6 (14.5)||81.9 (14.8)||.001a|
|Hyperthyroid symptom scale, mean (SD)||12.5 (10.0)||0.5 (2.8)||<.001d|
|Thyroid function test|
|Free thyroxine (ng/dL), mean (SD)||3.08 (1.09)||1.36 (0.12)||<.001a|
|Thyroid stimulating hormone (mIU/L), median (IQRe)||0.01 (0.00)||1.33 (1.19)||<.001d|
|Thyrotropin-binding inhibitory immunoglobulin (IU/L), median (IQR)||4.2 (10.3)||—||—|
|Glucose (mg/dL), mean (SD)||105.8 (18.6)||96.6 (23.1)||.24a|
|Blood urea nitrogen (mg/dL), mean (SD)||13.0 (2.9)||11.7 (2.4)||.20a|
|Creatinine (mg/dL), mean (SD)||0.50 (0.20)||0.69 (0.19)||.01a|
|Total cholesterol (mg/dL), mean (SD)||141.7 (22.1)||180.2 (22.8)||<.001a|
|Total protein (g/dL), mean (SD)||7.1 (0.5)||7.2 (0.4)||.37a|
|Albumin (g/dL), mean (SD)||4.3 (0.3)||4.4 (0.3)||.17a|
|Total bilirubin (mg/dL), mean (SD)||0.69 (0.30)||0.65 (0.26)||.69a|
|Aspartate aminotransferase (mg/dL), mean (SD)||26.4 (10.4)||18.3 (3.1)||.001a|
|Alanine aminotransferase (mg/dL), mean (SD)||33.1 (22.0)||15.1 (7.9)||.02a|
|White blood count (no/mm3), mean (SD)||5347.3 (1980.1)||5857.0 (1397.6)||.46a|
|Hemoglobin (mg/dL), mean (SD)||14.0 (1.44)||13.6 (1.4)||.42a|
|Platelet (no/mm3), mean (SD)||182,200 (118,600)||276,600 (59,100)||.02a|
aDerived from Student t test.
bDerived from Fisher exact probability test.
cbpm: beats per minute.
dDerived from Mann Whitney U test.
eIQR: interquartile range.
|Thyroid function test results and associated parameters||Visit 1||Visit 2||Visit 3||Visit 4||Visit 5||P valuea|
|Thyrotoxicosis group, n||28||28||28||23||5||—|
|Free thyroxine (ng/dL), mean (SD)||3.08 (1.09)||2.02 (0.61)||1.66 (0.64)||1.60 (0.59)||1.96 (0.39)||<.001b|
|Thyroid stimulating hormone (mIU/L), median (IQRc)||0.01 (0.00)||0.01 (0.00)||0.01 (0.13)||0.01 (0.10)||0.01 (0.10)||.114d|
|Hyperthyroid Symptom Scale, median (IQR)||12.5 (10.0)||5.5 (7.8)||4.0 (8.8)||3.5 (4.5)||7.0 (4.5)||<.001d|
|On-site resting heart rate (bpme), mean (SD)||101.6 (14.5)||94.4 (15.4)||90.1 (17.6)||85.5 (12.0)||83.5 (4.0)||.015b|
|WD-rHR-ownf (bpm), mean (SD)||88.0 (11.5)||82.9 (10.9)||75.9 (8.8)||76.2 (8.0)||72.7 (7.2)||<.001b|
|WD-rHR-Fitbitg (bpm), mean (SD)||82.2 (12.5)||76.8 (9.5)||70.8 (8.4)||71.4 (7.8)||74.7 (9.8)||<.001b|
|Control group, n||10||10||10||—||—||—|
|Free thyroxine (ng/dL), mean (SD)||1.36 (0.12)||1.37 (0.13)||1.35 (0.10)||—||—||.285b|
|Thyroid stimulating hormone (mIU/L), median (IQR)||1.33 (1.19)||1.62 (2.21)||2.06 (1.21)||—||—||.236d|
|Hyperthyroid Symptom Scale, median (IQR)||0.5 (2.8)||0.0 (2.0)||0.0 (2.0)||—||—||.504d|
|On-site resting heart rate (bpm), mean (SD)||81.9 (14.8)||81.0 (13.2)||76.4 (11.2)||—||—||.250b|
|WD-rHR-own (bpm), mean (SD)||65.8 (8.0)||63.2 (7.4)||64.5 (9.2)||—||—||.374b|
|WD-rHR-Fitbit (bpm), mean (SD)||66.5 (8.2)||64.3 (7.3)||64.3 (7.7)||—||—||.101b|
aVisit 1 to 3 were compared both in thyrotoxicosis and control groups.
bDerived from ANOVA with repeated measures with a Greenhouse-Geisser correction.
cIQR: interquartile range.
dDerived from Friedman test.
ebpm: beats per minute.
fWD-rHR-own: the resting heart rate from wearable device derived by own algorithm.
gWD-rHR-Fitbit: the resting heart rate from wearable device derived by Fitbit algorithm.
Association Between Serum Free Thyroxine Levels and Each Associated Parameter
Linear model GEE analyses were performed to verify the relationship between serum free T4 levels and each associated parameter (ie, HSS, on-site rHR, WD-rHR-own, and WD-rHR-Fitbit). In these analyses, the mean (SD) of each parameter were standardized to 0 and 1, respectively, to compare each parameter’s relationship with free T4 levels and with each other. Before standardization, the 1SD of HSS, on-site rHR, WD-rHR-own, and WD-rHR-Fitbit were 6.3, 15.8, 11.4, and 11.2, respectively in thyrotoxic patients and 6.3, 16.2, 11.4, and 11.4 in all study participants. Although all parameters analyzed were significantly associated with serum free T4 levels in thyrotoxicosis patients and in all study participants, unstandardized beta for serum free T4 level by an increase of 1 SD of on-site rHR was relatively lower than those of other parameters (). To control thyrotoxicosis symptoms, some patients took a beta blocker intermittently. We performed the same analysis, dividing the patient group into beta blocker users (n=13) and nonbeta blocker users (n=15), which did not change the interpretation of the results ( ).
Odds Ratio of Each Associated Parameter for Thyrotoxicosis
The relationship between thyrotoxicosis, defined as 1.8 ng/dL or more of free T4, and each associated parameter was assessed with binary logistic model GEE analyses. All parameters analyzed were significant for predicting thyrotoxicosis (). Also, in this analysis, OR for thyrotoxicosis by a 1 SD increase in on-site rHR was relatively lower than those of other parameters, HSS, WD-rHR-own, and WD-rHR-Fitbit, which showed similar ORs ( ). These findings were consistent when analyzing beta blocker users and nonusers separately, except that on-site rHR was nonsignificant for predicting thyrotoxicosis in the nonbeta blocker users ( ).
|Association between free thyroxine and parameters||Unstandardized beta||95% CI||P value|
|Thyrotoxicosis group only|
|Hyperthyroid Symptom Scale||.504||0.333-0.674||<.001|
|On-site resting heart rate||.362||0.122-0.602||.003|
|Hyperthyroid Symptom Scale||.541||0.394-0.687||<.001|
|On-site resting heart rate||.396||0.204-0.588||<.001|
aWD-rHR-own: resting heart rate from wearable device derived by own algorithm.
bWD-rHR-Fitbit: resting heart rate from wearable device derived by Fitbit algorithm.
|Association between free thyroxine and parameters||Odds ratio||95% CI||P value|
|Thyrotoxicosis group only|
|Hyperthyroid Symptom Scale||2.614||1.612-4.238||<.001|
|On-site resting heart rate||1.648||1.047-2.594||.031|
|Hyperthyroid Symptom Scale||3.601||2.190-5.923||<.001|
|On-site resting heart rate||2.114||1.365-3.273||<.001|
aWD-rHR-own: resting heart rate from wearable device derived by own algorithm.
bWD-rHR-Fitbit: resting heart rate from wearable device derived by Fitbit algorithm.
To evaluate the clinical feasibility of wearable device generated data for the management of thyrotoxicosis, we investigated the association between HR data collected by activity trackers and thyroid function across the clinical course of thyrotoxicosis. Our results demonstrated that both rHR measured by a wearable device and HSS were significantly associated with thyroid function.
It is well known that the thyroid hormone has a positive chronotropic, inotropic effect, meaning that it stimulates the rate and force of systolic contraction and the rate of diastolic relaxation . Therefore, thyrotoxicosis increases systolic blood pressure and HR and widens pulse pressure [ ]. In this study, the thyrotoxicosis group showed elevated on-site rHR compared with the control group. Mean values for systolic and diastolic blood pressures were higher in the thyrotoxicosis group, but this difference was not statistically significant. Also, several parameters known to be associated with thyroid function differed between the thyrotoxicosis and control groups. Many studies have reported that the thyrotoxic condition decreases serum creatinine levels [ , ] and improves lipid profiles, including total cholesterol [ , ]. Thyrotoxicosis increases liver enzyme levels owing to relative hypoxia in the hepatic perivenular regions [ , ]. Although reports have conflicted, relatively low platelet counts in thyrotoxic patients have also been reported [ , ]. Our baseline results were consistent with these previous reports.
HSS, on-site rHR, WD-rHR-own, and WD-rHR-Fitbit were decreased as thyrotoxicosis improved and these variables were all associated with serum free T4 levels and thyrotoxicosis in linear and binary logistic model GEE analyses, respectively. Interestingly, standardized on-site rHR showed relatively lower beta for serum free T4 level and a lower OR for thyrotoxicosis compared with other standardized parameters in the GEE analyses. On-site rHR is a one-time measurement of one clinical aspect, while HSS is a one-time measurement of several clinical aspects and WD-rHR is calculated from continuously monitored data for one clinical aspect. These differences can explain on-site rHR’s relatively weak correlation with thyroid function compared with HSS or WD-rHR. Similar beta and ORs and their 95% CIs between standardized HSS and WD-rHR suggest that WD-rHR calculated from continuously collected, detailed data by wearable devices may be used to assess thyroid function status with similar accuracy and precision with HSS, a validated assessment tool known to reflect thyroid function, but which also requires time and an educated scorer [, ]. Considering the time and effort required for evaluating HSS, WD-rHR, a simple parameter based on a large volume of detailed HR and activity data, could be a better predictor because the patient could get the results only by wearing the device. Even if patients measure their rHR manually between clinic visits, they still need to maintain a resting position without activity for 10 to 15 minutes. This makes it callenging to measure rHR manually several times daily. Taken together, WD-rHR is not only as accurate as a multi-dimensional assessment tool developed for evaluating thyrotoxic status, but also easier to measure compared with other assessment tools or conventional methods of measuring rHR.
Current wearable devices allow highly detailed, longitudinal measurement of physical indices. This large volume of clinical information (ie, “high definition data”) may provide more accurate and objective information than subjective symptoms or physical signs recorded at clinic visits, which can be influenced by diurnal variation, emotional state, and other factors . In this study, we calculated rHR from continuously monitored HR and physical activity data. Similar to manually measured HR, HR measured by wearable devices can also be affected by various factors, such as body position or emotional state. This influence cannot be selectively removed in the process of extracting rHR from collected HR data because these factors cannot be detected by the device we used. With the algorithm we used to calculate rHR, we could remove only the influence of physical activity, which can be detected by the device. However, continuously monitored high definition data could blunt the influence of other factors. As mentioned above, we selected rHR as a median HR value from data collected within a given time window without physical activity during the day. This algorithm might minimize the effect of daily repeated short-term factors such as emotional state or body position. However, long-term and continuous factors, such as disease status, still influence the data. Therefore, WD-rHR-own might reflect the disease state of thyrotoxicosis more accurately than on-site rHR. Although the algorithm for extracting resting HR provided by Fitbit is proprietary and undisclosed, the basic concept is not different from ours, and WD-rHR-Fitbit showed a similar association with thyroid function compared with WD-rHR-own. Based on the results of the present study, we suggest that WD-rHR shows reasonable a prediction of thyroid function in thyrotoxic patients. Also, the development of a wearable device capable of measuring other parameters such as sweating, tremor, or respiration rate would further improve accurate prediction of thyroid function status. Therefore, “high-definition medicine”, through wearable devices, shows current capability and future potential in its clinical application in this field.
This study has some significant clinical implications. Although monitoring thyroid function using wearable devices cannot replace TFT, it could aid the management of thyrotoxicosis. During the treatment of GD, most patients are expected to repeat the TFT every one to two months regardless of their response to ATDs, and the interventions including dose adjustment of ATDs are provided with the same time interval. Monitoring thyroid function using wearable devices may provide patients with individualized, flexible, and more accurate interventions during treatment and follow-up, minimizing inconvenience and costs. Moreover, about 50% of patients have been reported to relapse within two years after discontinuing ATD, even if they were treated according to the recommended guidelines . Monitoring during everyday life using wearable devices may enable early detection of disease recurrence in patients who are in remission after treatment. Although further studies are needed, these results may be applied to the monitoring of drug-induced subclinical thyrotoxicosis in patients with differentiated thyroid cancer (DTC) who are undergoing TSH-suppressive therapy (ie, maintaining iatrogenic subclinical thyrotoxic status using thyroid hormone over-replacement). TSH suppressive therapy is recommended to prevent the growth of DTC [ ], but over-suppression of TSH increases risks of fracture and cardiovascular disease [ - ]. Therefore, a simple monitoring tool during TSH-suppressive therapy, such as a wearable device in everyday life, might help maintain appropriate intensities of TSH suppression. We have developed a web application to predict thyrotoxicosis using rHR data from wearable devices [ ] based on the results of this study. Since the present study was a small, observational, preliminary study, additional studies are planned to investigate the clinical usefulness of this application for thyrotoxic patients and DTC patients undergoing TSH suppressive therapy.
The primary strength of the study was that it contributes to the literature by monitoring HR throughout the day using wearable devices, for the first time, in patients with thyrotoxicosis. The clinical evidence provided herein may inspire further investigations and clinical applications of biosignals monitored by wearable devices in thyroid dysfunction. The other strength is that we used commercially available wearable devices and mobile applications. Thus, our results can be immediately applied to the management of thyrotoxic patients and provide a ready-to-use algorithm for making Web-based or mobile applications for managing thyrotoxicosis.
This study also has some limitations, which should be considered when interpreting the results. First, it was likely easier for younger people, who are adept at using mobile phones and wearable devices, to participate in the study, although the participants’ ranged from 18 to 60 years of age. Also, signs such as increased HR owing to thyrotoxicosis may not be as evident in the elderly . Therefore, it may be difficult to apply the results of this study to those aged over 65 years. However, the ages of the participants in this study were similar to the population in which thyrotoxicosis is most prevalent, and the results of this study can likely be applied to those who can use mobile phones and wearable devices. Second, this study has a small sample size and imbalance between patient and control group sizes, as well as the single-center based design. Among the 30 thyrotoxic patients, only 3 patients were diagnosed as thyroiditis, and we could not perform statistical analyses in these three patients separately. We analyzed the patients with GD only, and the results showed the same tendency as those in all patients ( ). Despite the imbalance between patient and control group sizes, all statistical powers of the analyses in and were over 90%. Further investigations, including more participants and study sites, are needed to confirm the results of this study.
In conclusion, our results indicate that rHR data from wearable devices show reasonable predictability of thyroid function in patients with thyrotoxicosis. This parameter can be measured relatively simply and may be useful as well as clinically feasible for the management of thyroid dysfunction. This study is a starting point for the clinical application of high-definition medicine in the management of thyroid disease.
Funding for this study was provided by Seoul National University Bundang Hospital, which had no role in designing the study, data collection, analysis, or interpretation, writing the report, or decisions regarding submitting the paper for publication. This research was also supported by a research grant (02-2016-035) from the Seoul National University Bundang Hospital to JHM.
JHM was responsible for conception and design of the work. JHM, JEL, KMK, and TJO collected the data. JHM and JEL analyzed the data and drafted the manuscript. JHM, JEL, DHL, SHC, SL, YJP, DJP, and HCJ contributed data interpretation. JHM and JEL approved the final version of the manuscript. All authors agreed on the ﬁnal content of the manuscript.
Conflicts of Interest
Multimedia Appendix 1
Inclusion and exclusion criteria, biochemical measurements, and generalized estimating equations analyses.PDF File (Adobe PDF File), 53KB
- Cho BY. Clinical Thyroidology. In: 4th ed. Seoul, South Korea: Korea Medical Book Publishing Company; 2014.
- Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 1991 May;229(5):415-420. [Medline]
- Moon JH, Yi KH. The diagnosis and management of hyperthyroidism in Korea: consensus report of the korean thyroid association. Endocrinol Metab (Seoul) 2013 Dec;28(4):275-279 [FREE Full text] [CrossRef] [Medline]
- Devereaux D, Tewelde SZ. Hyperthyroidism and thyrotoxicosis. Emerg Med Clin North Am 2014 May;32(2):277-292. [CrossRef] [Medline]
- Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010 Jun;95(6):2715-2726. [CrossRef] [Medline]
- Goichot B, Caron P, Landron F, Bouée S. Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France: relationships with age, aetiology and hormonal parameters. Clin Endocrinol (Oxf) 2016 Mar;84(3):445-451. [CrossRef] [Medline]
- Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 2005 Aug;26(5):704-728. [CrossRef] [Medline]
- Crooks J, Marray IP, Wayne EJ. Statistical methods applied to the clinical diagnosis of thyrotoxicosis. Q J Med 1959 Apr;28(110):211-234. [Medline]
- Kalra S, Khandelwal SK, Goyal A. Clinical scoring scales in thyroidology: A compendium. Indian J Endocrinol Metab 2011 Jul;15(Suppl 2):S89-S94 [FREE Full text] [CrossRef] [Medline]
- Thompson W. Worldwide Survey of Fitness Trends for 2016; 10th Anniversary Edition. ACSM's Health & Fitness Journal 2015;19(6):9-18. [CrossRef]
- Park Associates global sales of connected digital fitness trackers will exceed 82 million in 2019 from? Investing in the Connected Health Market? At Connected Health Summit database on the Internet. 2015 URL: https://globenewswire.com/news [accessed 2018-07-04] [WebCite Cache]
- Tamura T, Maeda Y, Sekine M, Yoshida M. Wearable Photoplethysmographic Sensors—Past and Present. Electronics 2014 Apr 23;3(2):282-302. [CrossRef]
- Dooley EE, Golaszewski NM, Bartholomew JB. Estimating Accuracy at Exercise Intensities: A Comparative Study of Self-Monitoring Heart Rate and Physical Activity Wearable Devices. JMIR Mhealth Uhealth 2017 Mar 16;5(3):e34 [FREE Full text] [CrossRef] [Medline]
- Wang R, Blackburn G, Desai M, Phelan D, Gillinov L, Houghtaling P, et al. Accuracy of Wrist-Worn Heart Rate Monitors. JAMA Cardiol 2016 Oct 12. [CrossRef] [Medline]
- Fitbit. URL: https://www.fitbit.com/home [accessed 2017-05-29] [WebCite Cache]
- Klein I, Trzepacz P, Roberts M, Levey G. Symptom rating scale for assessing hyperthyroidism. Arch Intern Med 1988;148(2):4776-4790. [CrossRef]
- Lee JE, Lee DH, Oh TJ, Kim KM, Choi SH, Lim S, et al. Validity and Reliability of the Korean Version of the Hyperthyroidism Symptom Scale. Endocrinol Metab (Seoul) 2018 Mar;33(1):70-78 [FREE Full text] [CrossRef] [Medline]
- Fitbit. URL: http://dev.fitbit.com [accessed 2017-11-07] [WebCite Cache]
- Lee JE, Lee DH, Oh TJ, Kim KM, Choi SH, Lim S, et al. Clinical Feasibility of Continuously Monitored Data for Heart Rate, Physical Activity, and Sleeping by Wearable Activity Trackers in Patients with Thyrotoxicosis: Protocol for a Prospective Longitudinal Observational Study. JMIR Res Protoc 2018 Feb 21;7(2):e49 [FREE Full text] [CrossRef] [Medline]
- Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007 Oct 09;116(15):1725-1735 [FREE Full text] [CrossRef] [Medline]
- Basu G, Mohapatra A. Interactions between thyroid disorders and kidney disease. Indian J Endocrinol Metab 2012;16(2):204-213. [CrossRef]
- den Hollander JG, Wulkan RW, Mantel MJ, Berghout A. Correlation between severity of thyroid dysfunction and renal function. Clin Endocrinol (Oxf) 2005 Apr;62(4):423-427. [CrossRef] [Medline]
- Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 2012 Mar;96(2):269-281. [CrossRef] [Medline]
- Heimberg M, Olubadewo JO, Wilcox HG. Plasma lipoproteins and regulation of hepatic metabolism of fatty acids in altered thyroid states. Endocr Rev 1985;6(4):590-607. [CrossRef] [Medline]
- Kyriacou A, McLaughlin J, Syed AA. Thyroid disorders and gastrointestinal and liver dysfunction: A state of the art review. Eur J Intern Med 2015 Oct;26(8):563-571. [CrossRef] [Medline]
- Malik R, Hodgson H. The relationship between the thyroid gland and the liver. QJM 2002 Sep;95(9):559-569. [Medline]
- Dorgalaleh A, Mahmoodi M, Varmaghani B, et al. Effect of thyroid dysfunctions on blood cell count and red blood cell indice. Iran J Ped Hematol Oncol 2013;3(2):73-77 [FREE Full text] [Medline]
- Kurata Y, Nishioeda Y, Tsubakio T, Kitani T. Thrombocytopenia in Graves' disease: effect of T3 on platelet kinetics. Acta Haematol 1980;63(4):185-190. [Medline]
- Kolawole BA, Ikem RT, Lawal OO. Relationship between thyroid hormone levels and hyperthyroid signs and symptoms. Nig J Clinical Practice 2002;5(1):29-31 [FREE Full text]
- Trzepacz PT, Klein I, Roberts M, Greenhouse J, Levey GS. Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 1989 Nov;87(5):558-561. [Medline]
- Torkamani A, Andersen KG, Steinhubl SR, Topol EJ. High-Definition Medicine. Cell 2017 Aug 24;170(5):828-843. [CrossRef] [Medline]
- Kim YA, Cho SW, Choi HS, Moon S, Moon JH, Kim KW, et al. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study. Thyroid 2017 Dec;27(4):491-496. [CrossRef] [Medline]
- Haugen BR, Alexander EK, Bible KC. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26(1):1-133. [CrossRef]
- Cho SW. Effects of Thyroid Stimulating Hormone on Bone Metabolism. Int J Thyroidol 2016;9(2):127-130. [CrossRef]
- Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010 Jan;95(1):186-193. [CrossRef] [Medline]
- Klein HEN, Klein HMS, de BGH, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol 2013 Nov 10;31(32):4046-4053. [CrossRef] [Medline]
- Detect thyroid disease by your biosignals. URL: http://thyroscope.org [accessed 2018-07-04] [WebCite Cache]
|ANOVA: analysis of variance|
|ATD: antithyroid drug|
|CRF: case report form|
|DTC: differentiated thyroid cancer|
|GD: Graves’ disease|
|GEE: generalized estimating equation|
|HR: heart rate|
|HSS: Hyperthyroidism Symptom Scale|
|IQR: interquartile range|
|OR: odds ratio|
|SNUBH: Seoul National University Bundang Hospital|
|TFT: thyroid function test|
|TSH: thyroid hormone stimulating hormone|
|WD-rHR-Fitbit: resting heart rate from wearable device derived by Fitbit algorithm|
|WD-rHR-own: resting heart rate from wearable device derived by own algorithm|
Edited by G Eysenbach; submitted 18.01.18; peer-reviewed by J Taylor, J Pietilä, IN Gomez, K Ng, C Fincham; comments to author 08.02.18; revised version received 30.04.18; accepted 18.06.18; published 13.07.18Copyright
©Jie-Eun Lee, Dong Hwa Lee, Tae Jung Oh, Kyoung Min Kim, Sung Hee Choi, Soo Lim, Young Joo Park, Do Joon Park, Hak Chul Jang, Jae Hoon Moon. Originally published in JMIR Mhealth and Uhealth (http://mhealth.jmir.org), 13.07.2018.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR mhealth and uhealth, is properly cited. The complete bibliographic information, a link to the original publication on http://mhealth.jmir.org/, as well as this copyright and license information must be included.